Nutex Health Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Nutex Health heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 29%, terwijl de Healthcare-industrie de winst zag groeien met 11.6% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 31.8%. Het rendement op eigen vermogen van Nutex Health is 53.7%, en het heeft een nettomarge van 21.2%.
Belangrijke informatie
28.98%
Groei van de winst
-32.20%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 8.50% |
| Inkomstengroei | 31.76% |
| Rendement op eigen vermogen | 53.71% |
| Nettomarge | 21.25% |
| Laatste winstupdate | 30 Jun 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Seeking Alpha • Aug 12
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)
Summary Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods. With a 6.6x GAAP TTM PE, upside catalysts include the No Surprises Enforcement Act and $356 million in accounts receivable potentially converting to cash. Read the full article on Seeking Alpha
Narratiefupdate • Aug 10
NUTX: Arbitration Model And Margin Gains Will Support Future Upside
Nutex Health's analyst price target has shifted from $235.50 to $266.40. Analysts point to fresh coverage highlighting its micro hospital model, arbitration driven reimbursement approach, and capital light expansion plans as key factors in their updated views.Narratiefupdate • Jun 22
NUTX: Low EV EBITDA Multiple And Buyback Activity Will Support Future Upside
Analysts nudged their Nutex Health price target to $235, pointing to what they view as a low ~3x EV/EBITDA multiple, limited existing coverage, and ongoing investor confusion around the No Surprises Act as key factors behind their valuation work. What’s in the News for Nutex Health Nutex Health reported completing a share repurchase tranche between March 5, 2026 and March 31, 2026, buying 21,086 shares, or 0.3% of outstanding shares, for a total of US$3.02 million under the buyback announced on March 5, 2026.Narratiefupdate • Jun 04
NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential
Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
Narratiefupdate • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Narratiefupdate • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Narratiefupdate • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).Narratiefupdate • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Narratiefupdate • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Narratiefupdate • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Narratiefupdate • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Narratiefupdate • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Narratiefupdate • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Narratiefupdate • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Narratiefupdate • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Nieuw narratief • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Analyse-artikel • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analyse-artikel • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Analyse-artikel • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.Opbrengsten en kosten
Opbrengsten en kosten
Hoe Nutex Health geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 26 | 847 | 180 | -41 | 0 |
| 31 Mar 26 | 880 | 96 | 31 | 0 |
| 31 Dec 25 | 875 | 71 | 58 | 0 |
| 30 Sep 25 | 981 | 121 | 181 | 0 |
| 30 Jun 25 | 792 | 56 | 174 | 0 |
| 31 Mar 25 | 624 | 74 | 93 | 0 |
| 31 Dec 24 | 480 | 52 | 64 | 0 |
| 30 Sep 24 | 292 | -41 | 40 | 0 |
| 30 Jun 24 | 276 | -38 | 36 | 0 |
| 31 Mar 24 | 259 | -41 | 36 | 0 |
| 31 Dec 23 | 248 | -46 | 42 | 0 |
| 30 Sep 23 | 232 | -29 | 29 | 0 |
| 30 Jun 23 | 197 | -436 | 28 | 0 |
| 31 Mar 23 | 196 | -451 | 22 | 0 |
| 31 Dec 22 | 219 | -425 | 20 | 0 |
| 30 Sep 22 | 229 | -396 | 19 | 0 |
| 30 Jun 22 | 319 | 70 | 17 | 0 |
| 31 Mar 22 | 336 | 122 | 16 | 0 |
| 31 Dec 21 | 332 | 133 | 5 | 0 |
| 30 Sep 21 | 374 | 159 | 25 | 0 |
| 31 Dec 20 | 274 | 106 | 10 | 0 |
| 31 Dec 19 | 97 | 21 | 20 | 0 |
Kwaliteitswinsten: NUTX heeft een grote eenmalige verlies van $117.0M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2026.
Groeiende winstmarge: De huidige netto winstmarges (21.2%) NUTX } zijn hoger dan vorig jaar (7.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NUTX is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 29% per jaar laten groeien.
Versnelling van de groei: De winstgroei van NUTX over het afgelopen jaar ( 219.3% ) overtreft het 5-jarig gemiddelde ( 29% per jaar).
Winst versus industrie: De winstgroei NUTX over het afgelopen jaar ( 219.3% ) overtrof de Healthcare -sector 20.8%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 53.7% ) van NUTX wordt als uitstekend beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/24 11:34 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Nutex Health Inc. wordt gevolgd door 6 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| William Sutherland | Benchmark Company |
| Anderson Schock | B. Riley Securities, Inc. |
| Eugene Mannheimer | Freedom Capital Markets |